cas 35856-61-2|| where to buy N-ethyl-N-methylsulfamoyl chloride

Nom du produit:N-ethyl-N-methylsulfamoyl chloride

IUPAC Name:N-ethyl-N-methylsulfamoyl chloride

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM737575-5g	in stock	źŔư

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 35856-61-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:35856-61-2; Formule moléculaire:C3H8ClNO2S; Point de fusion:-; Code SMILES:CCN(C)S(Cl)(=O)=O; Densité:

: Numéro de catalogue:CM737575; Poids moléculaire:157.61; Point d'ébullition:; N° Mdl:MFCD11622866; Stockage:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Plixorafenib; FORE Biotherapeutics’s Plixorafenib (PLX-8394) is a next-generation, orally selective inhibitor and specific dimer breaker of BRAF protein under clinical development. Its favorable efficacy and tolerability are updated in the recently presented phase 1/2a results in BRAF V600 advanced solid tumors. Plixorafenib was designed to target a wide range of BRAF mutations while sparing wild type forms of RAF. It has been granted Fast Track Designation and Orphan Drug Designation from the U.S. FDA.